Melbourne, Australia; 22 June 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that an investor presentation by Chief Executive Officer, Dr Jackie Fairley, will be broadcast at 10:00 am EDT on Thursday, 22 June 2023 (12:00 am AEST on Friday, 23 June 2023), as part of the OTCQX’s Virtual Life Sciences Investor Forum.

The Life Sciences Investor Forum is a leading, virtual investor conference that provides a forum for public companies to present to retail and institutional investors as well as advisors.

The CEO’s pre-recorded presentation will provide an overview of Starpharma’s business including:

• Recent progress across Starpharma’s internal clinical DEP® programs including for both the Phase 2 DEP® cabazitaxel and DEP® docetaxel (monotherapy) trials, which have completed recruitment and treatment of patients, as well as the DEP® irinotecan Phase 2 trial.
• The latest preclinical results for Starpharma’s HER2-targeted DEP® antibody-drug conjugate (ADC), which utilised the active metabolite of irinotecan, SN-38, showed significantly greater anti-tumour activity and improved survival compared to the marketed ADC, Enhertu®, in a HER2+ human cancer xenograft model.
• An overview of Starpharma’s partnership with AstraZeneca and the clinical development of AZD0466, which utilises Starpharma’s DEP® technology to deliver and widen the therapeutic window of a Bcl-2/xL inhibitor and is the subject of two global Phase 1/2 clinical trials recruiting patients with advanced blood cancers at over 40 sites globally.
• Regulatory and commercial progress for Starpharma’s in-market products, including Viraleze™ and VivaGel® BV.

The presentation is appended and will also be made available on Starpharma’s website: www.starpharma.com.

View the full ASX Announcement, here.

View/Download the Investor Presentation here.